Biological E To Buy Dynavax's CpG 1018 Adjuvant For COVID-19 Vaccine Candidate

(RTTNews) - Biological E. Limited, a Hyderabad-based vaccine and pharmaceutical company, agreed to buy CpG 1018 adjuvant from Dynavax Technologies Corp. (DVAX) for use in the commercial production of Biological E's COVID-19 vaccine candidate, CORBEVAX.

The companies have extended their commercial supply agreement through 2022. The agreement includes doses for delivery in 2021, which were manufactured under the previously announced funding agreement between the Coalition for Epidemic Preparedness Innovations (CEPI) and Dynavax. Pending conditional regulatory approvals in India, Biological E expects to commence product launch of CORBEVAX later this year.

Last month, India's Union Ministry of Health finalized arrangements with Biological E. to reserve 300 million doses of CORBEVAX.